Zinc picolinate
Based on 1 Customer Validation
Zinc picolinate is an orally effective zinc supplement. Zinc picolinate reduces the expression of Hsp70, inhibits oxidative DNA damage, increases serum ALP activity, decreases MDA concentration, elevates SOD levels, and raises zinc concentrations in serum, whole body and plasma. Zinc picolinate does not alter copper and manganese contents in rainbow trout. Zinc picolinate exerts a protective effect against Acetic acid (HY-Y0319)-induced experimental colitis in Sprague Dawley rats. Zinc picolinate reduces uterine fibroid volume, alleviates colonic oxidative damage, relieves colonic inflammation, and enhances intestinal barrier integrity. Zinc picolinate can be used in research related to uterine fibroids, ulcerative colitis and chronic obstructive pulmonary disease.
For research use only. We do not sell to patients.
- Purity: ≥97.0%
- CAS No.: 17949-65-4
- Formula: C12H8N2O4Zn
- Molecular Weight:309.58
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
HSP70 |
Zinc picolinate (dietary zinc content 30-60 mg Zn/kg; oral administration; twice daily; for 55 days) linearly reduces oxidative stress (measured by MDA concentration) in rainbow trout, increases their serum ALP activity and tissue zinc levels, and does not affect their growth, feed intake, feed efficiency, or copper/manganese concentrations[2].
Zinc picolinate (6 mg/kg; i.p.; once daily; for 10 consecutive days) exerts a protective effect against acetic acid-induced ulcerative colitis in male Sprague Dawley rats by alleviating oxidative stress, inhibiting local and systemic inflammation, enhancing intestinal barrier integrity, and improving histopathological outcomes, while significantly reducing colonic TNF-α levels and histopathological scores[3].
Zinc picolinate (6 mg/kg; i.p.; once daily; for 10 consecutive days) regulates the expression of colonic cytokines and tight junction proteins in healthy male Sprague Dawley rats, significantly increases colonic TNF-α levels, decreases colonic IL-6, occludin-1 and claudin-1 levels, and does not alter macroscopic or histopathological results[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Coturnix coturnix japonica (6-month-old)[1]
-
Dosage:30 mg/kg of diet; 60 mg/kg of diet
-
Administration:p.o.; ad libitum daily; 350 days
-
Result:Showed no significant difference in tumor incidence between treatment and control groups (10% for 30 mg/kg group, 14% for 60 mg/kg group, vs. 16% control).
Reduced average tumor diameters significantly: 2.6 mm for the 30 mg/kg group and 2.9 mm for the 60 mg/kg group, compared to 4.8 mm in controls (P = .01).
Reduced serum oxidative stress markers significantly in a linear dose-dependent manner (P = .01): serum MDA was 1.34 μmol/L (30 mg/kg) and 0.93 μmol/L (60 mg/kg) vs. 1.95 μmol/L control; serum 8-isoprostane was 93 pg/mL (30 mg/kg) and 85 pg/mL (60 mg/kg) vs. 108 pg/mL control; serum HAE was 1.21 μmol/L (30 mg/kg) and 0.96 μmol/L (60 mg/kg) vs. 1.55 μmol/L control; serum 8-OHdG was 23.6 ng/mL (30 mg/kg) and 20.1 ng/mL (60 mg/kg) vs. 28.5 ng/mL control.
Decreased Hsp70 expression in fibroid tissue significantly in a dose-dependent manner (P < .05), with densitometric readings showing ~73% of control levels for the 30 mg/kg group and ~39% of control levels for the 60 mg/kg group.
-
Animal Model:Oncorhynchus mykiss (0+ y-old, initial average weight 50 g)[2]
-
Dosage:30 mg Zn/kg of diet; 60 mg Zn/kg of diet
-
Administration:p.o.; twice daily; 55 days
-
Result:Decreased serum malondialdehyde (MDA) concentration to 1.12 nmol/mL, liver MDA to 3.30 nmol/mL, and muscle MDA to 2.15 nmol/mL at 30 mg Zn/kg of diet.
Decreased serum MDA concentration to 0.92 nmol/mL, liver MDA to 2.94 nmol/mL, and muscle MDA to 1.63 nmol/mL at 60 mg Zn/kg of diet.
Increased serum alkaline phosphatase (ALP) activity to 115 U/L, serum Zn concentration to 13.8 μg/mL, and whole body Zn concentration to 47.8 μg/g at 30 mg Zn/kg of diet.
Increased serum ALP activity to 138 U/L, serum Zn concentration to 15.6 μg/mL, and whole body Zn concentration to 52.0 μg/g at 60 mg Zn/kg of diet.
Did not significantly alter body weight gain, feed intake, feed efficiency, or serum/whole body Cu and Mn concentrations at either dose compared to unsupplemented controls.
Decreased serum, liver, and muscle MDA concentrations linearly (P=0.001) with increasing zinc picolinate dose.
Increased serum ALP activity (P=0.01), serum Zn (P=0.01), and whole body Zn (P=0.05) linearly with dose.
-
Animal Model:Sprague Dawley (male, 12-week-old, 250-300 g, acetic acid-induced ulcerative colitis)[3]
-
Dosage:6 mg/kg
-
Administration:i.p.; daily; 10 days
-
Result:Attenuated ulcer severity and significantly reduced macroscopic damage score (p < 0.01) and stool consistency score (p < 0.05).
Significantly increased serum zinc levels (p < 0.05).
Significantly reduced colon malondialdehyde (MDA) levels (p < 0.05) and increased colon glutathione (GSH) levels (p < 0.01).
Significantly reduced colon myeloperoxidase (MPO) activity (p < 0.01), serum tumor necrosis factor (TNF)-α levels (p < 0.05), serum interleukin (IL)-6 levels (p < 0.01), colon TNF-α levels (p < 0.001), and colon IL-6 levels (p < 0.001).
Significantly increased colon occludin mRNA expression (p < 0.001) and claudin-1 mRNA expression (p < 0.001), and significantly reduced zonula occludens-1 mRNA expression (p < 0.001).
Significantly reduced histopathological score (p < 0.001) and increased PAS-positive surface mucus and goblet cell count.
-
Animal Model:Sprague Dawley (male, 12-week-old, 250-300 g)[3]
-
Dosage:6 mg/kg
-
Administration:i.p.; daily; 10 days
-
Result:Showed no significant changes in macroscopic score, stool quality score, colonic edema score, colon MDA levels, colon GSH levels, colon MPO levels, serum TNF-α levels, serum IL-6 levels, or histopathological score compared to saline-treated healthy rats.
Significantly increased colon TNF-α levels (p < 0.05) and significantly reduced colon IL-6 levels (p < 0.01) compared to saline-treated healthy rats.
Significantly reduced colon occludin-1 mRNA expression (p < 0.001) and claudin-1 mRNA expression (p < 0.001) compared to saline-treated healthy rats; no significant change in zonula occludens mRNA expression.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 17949-65-4
-
Appearance Solid
-
Molecular Weight 309.58
-
Formula C12H8N2O4Zn
-
Color White to off-white
-
SMILES
O=C1[O-][Zn+2]2([N]3=C1C=CC=C3)[O-]C(C4=[N]2C=CC=C4)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 20 mg/mL (64.60 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (6.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2 mg/mL (6.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (292 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sahin N, et al. Zinc picolinate in the prevention of leiomyoma in Japanese quail. J Med Food. 2009 Dec;12(6):1368-74. [Content Brief]
[3]. Han G, et al. Zinc Picolinate Mitigates Colonic Inflammation and Enhances Barrier Function in a Rat Model of Ulcerative Colitis. Biol Trace Elem Res. 2026 Apr;204(4):2285-2300. [Content Brief]
[4]. Kirkil G, et al. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med. 2008 Jun;102(6):840-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2302 mL | 16.1509 mL | 32.3018 mL | 80.7546 mL |
| 5 mM | 0.6460 mL | 3.2302 mL | 6.4604 mL | 16.1509 mL | |
| 10 mM | 0.3230 mL | 1.6151 mL | 3.2302 mL | 8.0755 mL | |
| 15 mM | 0.2153 mL | 1.0767 mL | 2.1535 mL | 5.3836 mL | |
| 20 mM | 0.1615 mL | 0.8075 mL | 1.6151 mL | 4.0377 mL | |
| 25 mM | 0.1292 mL | 0.6460 mL | 1.2921 mL | 3.2302 mL | |
| 30 mM | 0.1077 mL | 0.5384 mL | 1.0767 mL | 2.6918 mL | |
| 40 mM | 0.0808 mL | 0.4038 mL | 0.8075 mL | 2.0189 mL | |
| 50 mM | 0.0646 mL | 0.3230 mL | 0.6460 mL | 1.6151 mL | |
| 60 mM | 0.0538 mL | 0.2692 mL | 0.5384 mL | 1.3459 mL |
Zinc picolinate Related Classifications
HY-W459577 Related Classifications
Powered by Bioz